MedTrace Logo

COVID-19: Salvage TOcilizumab as a Rescue Measure

NCT04577534 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2021-06-21

No results posted yet for this study

Summary

Evaluating the efficacy of Tocilizumab in hospitalized patients in the inflammatory phase of COVID-19. Randomization 2:1 (TCZ:standard of care).

Conditions

  • Covid19

Interventions

DRUG

iv Tocillizumab (TCZ)

Participants are randomized (2:1) to receive TCZ or Standard of Care

Sponsors & Collaborators

  • Jarmo Oksi

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-14
Primary Completion
2021-06-16
Completion
2021-06-16

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04577534 on ClinicalTrials.gov